Abstract
The MYC family plays essential roles during brain development and their oncogenic deregulation is implicated in the formation of embryonal neural tumors such as medulloblastomas (MB) and neuroblastoma (NB). Amplification of the MYCN is the predominant marker for aggressive NB and correlates with poor prognosis, while c-MYC overexpression is a defining feature of MB subgroups inflected with aggressive biological behavior and increased likelihood of metastasis. Not surprisingly MYC has emerged as an attractive target for pediatric neural cancer therapy. However despite three decades of intensive research in MYC biology and an impressive number of 30,000 publications, inhibition of MYC as therapeutic strategy remains an elusive goal in cancer medicine. This review discusses the potential and challenges of targeting the oncogenic effects of MYC as therapeutic strategy for MYC over-expressing embryonal neural tumors where current therapies are inadequate.
Keywords: Embryonal tumors, medulloblastoma, MYC, neuroblastoma, pediatric cancer.
Current Cancer Drug Targets
Title:MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges
Volume: 16 Issue: 1
Author(s): Tarek Shalaby and Michael A. Grotzer
Affiliation:
Keywords: Embryonal tumors, medulloblastoma, MYC, neuroblastoma, pediatric cancer.
Abstract: The MYC family plays essential roles during brain development and their oncogenic deregulation is implicated in the formation of embryonal neural tumors such as medulloblastomas (MB) and neuroblastoma (NB). Amplification of the MYCN is the predominant marker for aggressive NB and correlates with poor prognosis, while c-MYC overexpression is a defining feature of MB subgroups inflected with aggressive biological behavior and increased likelihood of metastasis. Not surprisingly MYC has emerged as an attractive target for pediatric neural cancer therapy. However despite three decades of intensive research in MYC biology and an impressive number of 30,000 publications, inhibition of MYC as therapeutic strategy remains an elusive goal in cancer medicine. This review discusses the potential and challenges of targeting the oncogenic effects of MYC as therapeutic strategy for MYC over-expressing embryonal neural tumors where current therapies are inadequate.
Export Options
About this article
Cite this article as:
Shalaby Tarek and Grotzer A. Michael, MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges, Current Cancer Drug Targets 2016; 16 (1) . https://dx.doi.org/10.2174/1568009615666150916092745
DOI https://dx.doi.org/10.2174/1568009615666150916092745 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Micro-Nanomaterials for Tumor Microwave Hyperthermia: Design, Preparation, and Application
Current Drug Delivery C-peptide and Neuropathy in Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Prospects for Rational Development of Pharmacological Gap Junction Channel Blockers
Current Drug Targets Increased CRMP2 Phosphorylation is Observed in Alzheimers Disease; Does this Tell us Anything About Disease Development?
Current Alzheimer Research Low Concentration of Caffeine Inhibits the Progression of the Hepatocellular Carcinoma <i>via Akt</i> Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Current Drug Targets Impact of Diabetes in Blood-Testis and Blood-Brain Barriers: Resemblances and Differences
Current Diabetes Reviews Opioids and Cannabinoids Interactions: Involvement in Pain Management
Current Drug Targets The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets The Neuroprotective Effects of Purslane (Portulaca oleracea) on Rotenone- Induced Biochemical Changes and Apoptosis in Brain of Rat
CNS & Neurological Disorders - Drug Targets The Recent Development of α<sub>7</sub> Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases
Current Pharmaceutical Design Anticancer Mechanisms of Berberine: A Good Choice for Glioblastoma Multiforme Therapy
Current Medicinal Chemistry The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine A Novel Monoclonal Antibody Against the C-terminus of β-Tubulin Recognizes Endocytic Organelles in Trypanosoma cruzi
Protein & Peptide Letters Chemoprotection and Selection by Chemotherapy of Multidrug Resistance-associated Protein-1 (MRP1) Transduced Cells
Current Gene Therapy Emerging Technologies for Fertility Preservation in Female Patients
Current Women`s Health Reviews Glycogen Synthase Kinase-3: A Potential Target for Drug Discovery in the Treatment of Neurodegenerative Disorders
Current Enzyme Inhibition